$9.05
+1.7%ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Chief Business Officer
Chief Commercial Officer
Compensation
$618,614
Chief Financial Officer
Chief Legal Officer & Secretary
Compensation
$677,145
Chief Operating Officer
Compensation
$706,970
Co-Founder & Chief Medical Officer
Compensation
$2,936,973
Co-Founder & Chief Science Officer
Co-Founder, President, Chief Executive Officer & Director
Compensation
$3,332,915
Executive Vice President of Commercial Strategy
Senior Vice President of Marketing
During the last 12 months, insiders have sold $1.20M worth of SPRY shares, with no buying activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
51.8K
457.41K
-457K
-$457K
0
0.00
62.5K
743.10K
-743K
-$743K
No buying activity
Lowenthal Richard E
Director, 10 Percent Owner, Officer: President And Ceo
$724K
Chakma Justin
Officer: Chief Business Officer
$267K
Dorsey Brian
Officer: Chief Operating Officer
$190K
Scott Kathleen D.
Officer: Chief Financial Officer
$19K
Strong bearish signal with $1.20M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
4 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SPRY - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 24, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 25, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 20, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 01, 2023 | June 27, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 10, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 22, 2021 | June 04, 2021 | 2021 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.